Ronald Berenson
Fondateur chez KitoTech Medical, Inc.
Profil
Ronald J.
Berenson is the founder of KitoTech Medical, Inc. (founded in 2013) where he holds the title of Executive Chairman.
He was also the founder of CellPro, Inc. (founded in 1989) where he held the title of Director, EVP, Chief Medical & Scientific Officer.
Additionally, he was the founder of Cyclacel Pharmaceuticals, Inc. (founded in 1996) where he held the title of President & Chief Executive Officer.
He also founded HemaQuest Pharmaceuticals, Inc. (founded in 2007) where he held the title of President.
Furthermore, he is the founder of DMD Therapeutics, Inc. (founded in 2016) where he holds the title of President & Chief Executive Officer.
Dr. Berenson was also the founder of Xcyte Therapies, Inc., Viracta Subsidiary, Inc...Dr. Berenson's current job(s) included being the President & Chief Executive Officer at Aequus BioPharma, Inc. since 2012 and a Director at Fe3 Medical, Inc.Dr. Berenson's former job(s) included being a Director at Calypso Medical Technologies, Inc. and a Faculty Member at Fred Hutchinson Cancer Research Center.
Dr. Berenson's education history includes an undergraduate degree from Stanford University and a doctorate degree from Yale University.
Postes actifs de Ronald Berenson
| Sociétés | Poste | Début |
|---|---|---|
Fe3 Medical, Inc.
 Fe3 Medical, Inc. Medical SpecialtiesHealth Technology Fe3 Medical, Inc. develops a transdermal therapy for iron deficiency anemia. It offers a disposable transdermal patch that delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects. The company was founded by Mir A. Imran in 2008 and is headquartered in San Antonio, TX. | Directeur/Membre du Conseil | 20/05/2011 |
Aequus BioPharma, Inc.
 Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | Directeur Général | 10/12/2012 |
KitoTech Medical, Inc.
 KitoTech Medical, Inc. Medical SpecialtiesHealth Technology KitoTech Medical, Inc. operates as a medical device company which develops medical products based on its proprietary micro staple technology platform. It specializes in wound closure, patient care, emergency laceration, surgery, skin closure device, and biotechnology. The company was founded by Ronald J. Berenson and Marco Rolandi in 2013 and is headquartered in Seattle, WA. | Fondateur | 01/01/2013 |
DMD Therapeutics, Inc.
 DMD Therapeutics, Inc. BiotechnologyHealth Technology DMD Therapeutics, Inc. develops novel therapeutics for DMD and other muscular dystrophies. The company was founded by Carlo Rago and Ronald Berenson in 2016 and is headquartered in Seattle, WA. | Directeur Général | 01/01/2016 |
Anciens postes connus de Ronald Berenson
| Sociétés | Poste | Fin |
|---|---|---|
| CellPro, Inc. | Fondateur | 01/03/2009 |
| CYCLACEL PHARMACEUTICALS, INC. | Fondateur | 27/03/2006 |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Fondateur | - |
Calypso Medical Technologies, Inc.
 Calypso Medical Technologies, Inc. Medical/Nursing ServicesHealth Services Calypso Medical Technologies, Inc. provided radiation therapy and medical services. The company was founded by Eric R. Meier, Alfred G. Merriweather and Steve Tallman in 1999 and was headquartered in Seattle, WA. | Directeur/Membre du Conseil | - |
Fred Hutchinson Cancer Research Center
 Fred Hutchinson Cancer Research Center Miscellaneous Commercial ServicesCommercial Services Fred Hutchinson Cancer Research Center is a non-profit organization which provides research and testing services. The company was founded in 1965 and is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Formation de Ronald Berenson
| Stanford University | Undergraduate Degree |
| Yale University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CYCLACEL PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
| Xcyte Therapies, Inc. | Health Technology |
Calypso Medical Technologies, Inc.
Calypso Medical Technologies, Inc. Medical/Nursing ServicesHealth Services Calypso Medical Technologies, Inc. provided radiation therapy and medical services. The company was founded by Eric R. Meier, Alfred G. Merriweather and Steve Tallman in 1999 and was headquartered in Seattle, WA. | Health Services |
Fe3 Medical, Inc.
Fe3 Medical, Inc. Medical SpecialtiesHealth Technology Fe3 Medical, Inc. develops a transdermal therapy for iron deficiency anemia. It offers a disposable transdermal patch that delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects. The company was founded by Mir A. Imran in 2008 and is headquartered in San Antonio, TX. | Health Technology |
KitoTech Medical, Inc.
KitoTech Medical, Inc. Medical SpecialtiesHealth Technology KitoTech Medical, Inc. operates as a medical device company which develops medical products based on its proprietary micro staple technology platform. It specializes in wound closure, patient care, emergency laceration, surgery, skin closure device, and biotechnology. The company was founded by Ronald J. Berenson and Marco Rolandi in 2013 and is headquartered in Seattle, WA. | Health Technology |
| CellPro, Inc. | Health Technology |
Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center Miscellaneous Commercial ServicesCommercial Services Fred Hutchinson Cancer Research Center is a non-profit organization which provides research and testing services. The company was founded in 1965 and is headquartered in Seattle, WA. | Commercial Services |
HemaQuest Pharmaceuticals, Inc.
 HemaQuest Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology HemaQuest Pharmaceuticals, Inc. develops small molecule therapeutics. Its products include hydroxyurea, a therapeutic agent for the treatment of underlying pathology of sickle cell anemia and for the treatments of beta thalassemia, sickle cell anemia, neutropenia, and various hematological disorders. The company was founded by Ronald J. Berenson, Douglas V. Faller, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos and Robert Williams in October 2007 and is headquartered in San Diego, CA. | Health Technology |
Aequus BioPharma, Inc.
Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | Health Services |
DMD Therapeutics, Inc.
DMD Therapeutics, Inc. BiotechnologyHealth Technology DMD Therapeutics, Inc. develops novel therapeutics for DMD and other muscular dystrophies. The company was founded by Carlo Rago and Ronald Berenson in 2016 and is headquartered in Seattle, WA. | Health Technology |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |